Table III.
Use of circulating tumor DNA detection in various cancer types.
| Cancer | Diagnostic biomarker(s) | Sample size, n | Detection method(s) | (Refs.) |
|---|---|---|---|---|
| Head and neck squamous cell carcinoma | TP53 | 6 | ddPCR | (73) |
| Non-small cell lung cancer | EGFR, T790M | 10 | ddPCR | (74) |
| TP53, KRAS, EGFR | 68 | NGS | (75) | |
| EGFR, KRAS, PIK3CA, TP53 | 58 | Targeted sequencing | (76) | |
| Renal cell carcinoma | TP53, VHL, EGFR, NF1, ARID1A | 220 | NGS | (77) |
| MET | Immunohistochemistry, direct DNA sequencing, qPCR | (78) | ||
| Breast cancer | TP53 | 46 | ddPCR | (79) |
| TP53 | 40 | Microfluidic digital PCR | (80) | |
| ESR1, ERBB2, PIK3CA, AKT1 E17K | 96 | mdPCR | (81) |
ddPCR, droplet digital polymerase chain reaction; NGS, next generation sequencing; mdPCR, multiplex digital PCR.